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related event, adjusting for gender, age, ethnicity, presence
of co-morbid respiratory diseases, number of other co-
morbidities, pre-index use of short-acting beta agonists
(SABAs), oral steroids and theophylline, and pre-index
events. RESULTS: A total of 4447 patients were identi-
ﬁed, 2435 (55%) on IPR, 1088 (24%) on ICS alone, 410
(9%) on ICS + IPR, 299 (7%) on SAL alone and 215 (5%)
on ICS + SAL. Compared to IPR alone, the use of ICS
alone (HR 0.82, 95% CI: 0.69, 0.96), SAL alone (HR
0.62, 95% CI: 0.46, 0.84), and ICS + SAL (HR 0.64, 95%
CI: 0.45, 0.91) were associated with a lower event risk
when controlling for the other factors. Factors that were
signiﬁcant predictors of an increase risk of an event were:
being white, having a co-morbid respiratory disease,
using pre-index SABAs, and having pre-index events.
CONCLUSION: The results of this analysis suggest 
that the use of inhaled corticosteroids and salmeterol
were associated with a signiﬁcant decrease in the risk of
COPD-related hospital/ED events compared to the use of
IPR alone in a population of Medicaid patients. This was
an observational retrospective analysis and these data
should be conﬁrmed by prospective studies.
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OBJECTIVES: The purpose of this abstract is to examine
the use of long-term asthma controller medications
(LTACM) before and after asthma-related inpatient stays
and emergency department events (EDE). METHODS:
Data was drawn from the 1997 Medstat-Marketscan
claims database. Asthma-related events were deﬁned as
EDE or inpatient hospital stay with a primary or sec-
ondary diagnosis of asthma (ICD-9 code 493). LTACM
included corticosteroids, xanthines, leukotriene modiﬁers
and combination medications. RESULTS: The sample
included 464 individuals with an asthma-related EDE and
747 with an inpatient hospital stay. Of the EDE sample,
60% ﬁlled a prescription for LTACM during the calendar
year. A total of 32% had ﬁlled a prescription prior to the
EDE with an average of 85 days between the prescription
being ﬁlled and the EDE. Twenty percent ﬁlled a pre-
scription during the month subsequent to the EDE and
35% during the subsequent calendar year. Of those with
a hospital stay, 60% ﬁlled a prescription for LTACM
during the calendar year. Of those that ﬁlled a prescrip-
tion prior to the hospitalization, there was an average of
70.4 days between the ﬁlling of the prescription and the
event. Forty four percent of the hospital sample ﬁlled a
prescription afterward, with 65% doing so within 30
days. CONCLUSIONS: We ﬁnd that many of those
receiving care in inpatient ad emergency departments are
not using long-term controller medications. It is likely
that virtually all of these individuals have been prescribed
medications, but have not complied with the drug
regimen. Even after an adverse event, a slight majority
continues to not ﬁll prescriptions. One approach for
improving the health of those with asthma and reducing
asthma expenditures.
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OBJECTIVES: Montelukast has been approved for the
treatment of seasonal allergic rhinitis. The study’s objec-
tive was to compare allergic rhinitis (AR) associated
medical and pharmacy utilization in asthma patients with
comorbid AR initiating inhaled corticosteroids (ICS) or
montelukast (MO). METHODS: A retrospective, obser-
vational study using healthcare claims from 25 United
Healthcare plans was conducted. Subjects less than 65
years old and newly started on either ICS or MO between
01.01.1999 and 12.31.2000 were identiﬁed. Subjects
with at least one asthma (493.xx) and one AR (477.xx)
medical claim, 24 months of continuous enrollment, and
either an AR claim or a non-sedating antihistamine (NSA)
during the 12-month baseline were included. A logistic
propensity score model was constructed utilizing AR,
asthma and total health services utilization in the base-
line period and matched cohorts selected based on a
propensity score difference of £0.01. During the 12-
month follow-up, the total number of NSA and nasal 
corticosteroid (NCS) reﬁlls, total days supply of NSA
received, total AR pharmacy cost (not including asthma
medications) and total AR health services cost (pharmacy
+ medical) were determined. Wilcoxon rank sum was
used to test median differences in AR utilization.
RESULTS: A total of 1706 subjects were matched, (853
ICS and 853 MO). Compared to ICS subjects, MO sub-
jects received signiﬁcantly more reﬁlls for NSA (median
of 2.55 vs. 3.34, p < 0.0001), signiﬁcantly more days of
NSA therapy (median days supply of 30 vs. 60, p =
0.0001), and fewer NCS reﬁlls (median of 0.63 vs. 0.54,
p = 0.0459). Additionally, MO subjects had signiﬁcantly
higher median AR pharmacy cost ($130 vs. $107, p =
0.0028) and total AR cost ($279 vs. $214, p = 0.0180).
CONCLUSIONS: In this population, compared with ICS,
the use of MO in asthma subjects with comorbid AR was
associated with greater AR health services cost in the 
12-month follow-up period.
